BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

...Herpes zoster vaccine) Swedish Orphan Biovitrum AB Stemline Therapeutics Inc. GlaxoSmithKline plc AstraZeneca plc Adheron Therapeutics Inc. Gilead Sciences Inc. Blueprint Medicines Corp. Insmed Inc. Novartis...
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...company has raised more than $1.9 billion in four venture rounds. Insmed, Kura price follow-ons Insmed Inc....
...Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio A/S Limbix Kura Oncology Inc. Insmed...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

...and a miss for the high dose on a secondary endpoint, raise questions about how Insmed’s...
...from baseline of activated ELANE, another secondary endpoint (p=0.034 and p=0.021, respectively). A spokesperson for Insmed Inc....
...stopped selling the IGF-1 receptor agonist to new patients (see “Insmed combines with Transave” ). Insmed...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...who will become CMO of Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) in April, rare disease company Insmed Inc....
...and Elizabeth S. Eaton, Staff Writers Cell and Gene Therapy Catapult Los Angeles Biomedical Research Institute SutroVax Inc. NeoImmuneTech Inc. Insmed Inc. Moderna...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...president, CSO and board member at immuno-oncology company Tollnine, which he co-founded. Rare diseases company Insmed Inc....
...Affimed N.V. (NASDAQ:AFMD). Jonathan Block, Associate Editor Jonathan Block, Associate Editor, and Hongjiang Li, Staff Writer Lonza Group Ltd. Insmed Inc. Pfenex...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

...Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...5/23/19 $319.5 $6,504.5 $7,908.9 22% OncoSec Medical Inc. (NASDAQ:ONCS) (A) 5/22/19 $11.0 NA $26.9 NA Insmed Inc....
BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...VP and CFO, succeeding Ivor MacLeod. Coyle was VP of financial planning and analysis at Insmed Inc....
BioCentury | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

...Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of...
...discount to Insmed's Monday close of $28.07, when it proposed the offering after market close. Insmed...
...BIO101), a MAS receptor agonist in Phase IIb testing to treat sarcopenia. Chris Lieu, Staff Writer Biophytis S.A. Insmed...
BioCentury | Mar 29, 2019
Company News

Management tracks: Insmed, AACR, BlueRock

...Pulmonary disease company Insmed said Paolo Tombesi will step down as CFO and remain a consultant...
...said Paolo Tombesi will step down as CFO and remain a consultant, effective June 2. Insmed Inc....
...Kola, who was CSO at UCB S.A. (Euronext:UCB), will lead Forepont's Incubation Fund. BioCentury Staff AACR BlueRock Therapeutics Celyad S.A. Insmed Inc. Merck...
Items per page:
1 - 10 of 374
BioCentury | Jul 24, 2020
Regulation

Data Bytes: CHMP’s July recommendations

...Herpes zoster vaccine) Swedish Orphan Biovitrum AB Stemline Therapeutics Inc. GlaxoSmithKline plc AstraZeneca plc Adheron Therapeutics Inc. Gilead Sciences Inc. Blueprint Medicines Corp. Insmed Inc. Novartis...
BioCentury | May 7, 2020
Finance

May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta

...company has raised more than $1.9 billion in four venture rounds. Insmed, Kura price follow-ons Insmed Inc....
...Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio A/S Limbix Kura Oncology Inc. Insmed...
BioCentury | Feb 4, 2020
Product Development

Insmed planning Phase III for rare lung disorder therapy following mixed Phase II readout

...and a miss for the high dose on a secondary endpoint, raise questions about how Insmed’s...
...from baseline of activated ELANE, another secondary endpoint (p=0.034 and p=0.021, respectively). A spokesperson for Insmed Inc....
...stopped selling the IGF-1 receptor agonist to new patients (see “Insmed combines with Transave” ). Insmed...
BioCentury | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

...who will become CMO of Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) in April, rare disease company Insmed Inc....
...and Elizabeth S. Eaton, Staff Writers Cell and Gene Therapy Catapult Los Angeles Biomedical Research Institute SutroVax Inc. NeoImmuneTech Inc. Insmed Inc. Moderna...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...president, CSO and board member at immuno-oncology company Tollnine, which he co-founded. Rare diseases company Insmed Inc....
...Affimed N.V. (NASDAQ:AFMD). Jonathan Block, Associate Editor Jonathan Block, Associate Editor, and Hongjiang Li, Staff Writer Lonza Group Ltd. Insmed Inc. Pfenex...
BioCentury | Jul 23, 2019
Company News

Management tracks: Epizyme, Disarm, Kaleido, Selecta and more

...Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed Inc....
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...5/23/19 $319.5 $6,504.5 $7,908.9 22% OncoSec Medical Inc. (NASDAQ:ONCS) (A) 5/22/19 $11.0 NA $26.9 NA Insmed Inc....
BioCentury | Jun 4, 2019
Company News

Management tracks: Vericel, Theravance, Eisai

...VP and CFO, succeeding Ivor MacLeod. Coyle was VP of financial planning and analysis at Insmed Inc....
BioCentury | May 22, 2019
Financial News

May 22 Financial Quick Takes: $250M for Insmed; plus downgrade for Woodford and more

...Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale of...
...discount to Insmed's Monday close of $28.07, when it proposed the offering after market close. Insmed...
...BIO101), a MAS receptor agonist in Phase IIb testing to treat sarcopenia. Chris Lieu, Staff Writer Biophytis S.A. Insmed...
BioCentury | Mar 29, 2019
Company News

Management tracks: Insmed, AACR, BlueRock

...Pulmonary disease company Insmed said Paolo Tombesi will step down as CFO and remain a consultant...
...said Paolo Tombesi will step down as CFO and remain a consultant, effective June 2. Insmed Inc....
...Kola, who was CSO at UCB S.A. (Euronext:UCB), will lead Forepont's Incubation Fund. BioCentury Staff AACR BlueRock Therapeutics Celyad S.A. Insmed Inc. Merck...
Items per page:
1 - 10 of 374